FAQ: Quantum BioPharma's Response to Law Firm Allegations and Company Overview
Summary
Quantum BioPharma has formally rejected what it calls vague and unsubstantiated claims by The Schall Law Firm and DJS Law Group regarding alleged securities law violations, stating the announcements appear intended to mislead investors and provoke unwarranted concern.
What is the main topic of this announcement?
Quantum BioPharma has issued a formal response rejecting vague and unsubstantiated claims made by The Schall Law Firm and DJS Law Group regarding alleged securities law violations.
Why is Quantum BioPharma responding to these law firm announcements?
The company states that the announcements lack factual detail or context and appear intended to mislead investors and provoke unwarranted concern about the company.
What actions is Quantum BioPharma taking regarding these claims?
Quantum BioPharma is reviewing the conduct of both law firms and their principals and will take appropriate action to address what it believes is a deliberate attempt to harm its reputation.
What is Quantum BioPharma’s primary business focus?
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders.
What is Lucid-MS and what does it treat?
Lucid-MS is Quantum BioPharma’s lead compound, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
What is Quantum BioPharma’s relationship with Unbuzzd Wellness Inc.?
Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. and receives royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity.
Where can investors find more information about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
What other business activities does Quantum BioPharma engage in?
Through its wholly owned subsidiary FSD Strategic Investments Inc., Quantum BioPharma maintains a portfolio of strategic investments representing loans secured by residential or commercial property.
Where is the full press release available?
The full press release can be viewed at https://ibn.fm/TsBbx
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 251904